WATERTOWN, Mass.--(BUSINESS WIRE)--FORUM Pharmaceuticals Inc., a biopharmaceutical company singularly focused on the development and delivery of innovative medicines to treat serious brain diseases, today announced that it will participate in the 2015 Leerink Global Healthcare Conference in New York City. Deborah Dunsire, M.D., President and Chief Executive Officer of FORUM, will provide an overview of the Company and conduct meetings with institutional investors. The presentation is scheduled for Thursday, February 12, 2015, at 11:35 a.m. Eastern Time at the Waldorf Astoria Hotel.
About FORUM Pharmaceuticals Inc.
FORUM Pharmaceuticals Inc. (“FORUM Pharmaceuticals” or “FORUM”) is dedicated to developing groundbreaking medicines in support of all those who are affected by or caring for people with serious brain disease, to help them live fuller, more enriching lives. The Company’s robust and diverse pipeline is focused on discovering and developing new treatments for important neurodegenerative diseases that explore novel mechanisms of action to potentially alter the progression of brain disease and provide improvement in cognitive and overall function. FORUM’s lead compound, encenicline (EVP-6124), is currently being evaluated in separate ongoing Phase 3 clinical trial programs: COGNITIV SZ, which looks to improve cognitive impairment in patients with schizophrenia, and COGNITIV AD, which aims to improve cognition in patients with Alzheimer’s disease. The Company is also developing genetically-targeted therapies, including FRM-0334 for the potential treatment of frontotemporal dementia. Privately owned, FORUM Pharmaceuticals is based in Watertown, Mass. For more information about FORUM, visit www.forumpharma.com.
FORUM Pharmaceuticals and the FORUM octagon logo are trademarks of FORUM Pharmaceuticals Inc.